Nasal Alzheimer’s vaccine begins human trials for the first time
Brigham and Women’s Hospital in Boston, Massachusetts, will soon begin phase I trials of a nasal vaccine designed to prevent or slow the progression of Alzheimer’s disease (AD), said a press release. This is the first time a nasal vaccine has been attempted for the disease More than six million people In the United States alone.
It was first seen in a sick way in 1906 by Dr. Alois AlzheimerThe disease is a brain disorder characterized by clumps (amyloid plaques) and tangled fibers (tau tangles) between nerve cells (neurons) in the brain. Symptoms of the disease, which usually appear in adults in their 60s, range from memory problems to vision loss and even impaired thinking.
The cause of the disease has always been in question and it was only recently that researchers believed it to get to the root of it. The search for a cure has been going on for decades, however, and most interventions aim to reduce the severity of symptoms. The vaccine that will be tried aims to change this.
nasal vaccine trial
Howard L. Weiner, co-director of the Center that Studies Neurodegenerative Diseases at Brigham, has been researching the development of Alzheimer’s disease for more than 20 years. Previous studies have shown that the body’s immune cells play a role in clearing amyloid plaques from the brain. Therefore, researchers use an immune system called Protollin to stimulate the immune system and remove plaques.
Protulin is an intranasal agent derived by mixing specific cellular components from different bacteria and actually used as an adjuvant, to generate a greater immune response to other vaccines. The researchers hope that by stimulating the immune system, specifically white blood cells from the lymph node in the neck area, the vaccine will clear plaques in Alzheimer’s patients as well.
The trial will include 16 participants aged between 60 and 85 diagnosed with early-stage Alzheimer’s disease, the press release said. Trial participants will receive two doses of the vaccine, one week apart. The main goal of the trial is to determine if the vaccine is safe and tolerable at the planned doses. If successful, the same treatment method could be used for other neurodegenerative diseases, the press release said.
Interestingly, another possibility Vaccine and treatment strategy for AD was published earlier this month and will move to human trials soon.